About SOTIO
SOTIO is a Healthcare company based in Prague (Czechia) founded in 2010, and was acquired by PPF Group in June 2012. Activated dendritic cells are developed for cancer immunotherapy treatments. It operates on a Professional Services model. SOTIO has completed 1 acquisition, including CytunePharma. Its chief executive, as recorded, is Radek Spisek. SOTIO offers products and services including SOT106, SOT109, and Nanrilkefusp alfa. Its focus areas include Biotechnology and Oncology. Its legal entity is SOTIO Biotech a.s.
Company details
SOTIO Biotech is engaged in the development of next-generation immunotherapies for cancer treatment. The companys pipeline includes internally developed and in-licensed candidates targeting various solid tumor types. Solutions such as antibody-drug conjugates and immunocytokines are being advanced through clinical development to provide safer and more effective treatments. The focus is placed on translating scientific innovation into patient benefits within the oncology sector.
- Annual Revenue$8.12 K (USD)as on Dec 31, 2021
- Investors
- Investments & Acquisitions
- Acquired byPPF Group
(Jun 2012)
Products & Services of SOTIO
SOTIO offers a comprehensive portfolio of products and services, including SOT106, SOT109, and Nanrilkefusp alfa.
SOT106 is developed as an ADC targeting LRRC15.
SOT109 is designed to target cadherin-17 in cancers.
Nanrilkefusp alfa is developed for targeted immune activation.
Investors in SOTIO
SOTIO has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include PPF Group.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
PPF Group is engaged in international investment across diverse sectors. | 1991 | ppf.eu | Prague, Czech Republic |
Investor details for SOTIO
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of SOTIO
25 people are tracked at SOTIO (16 in leadership, 5 in board & advisors, 4 in team).
| Name | Role | Group |
|---|---|---|
Radek Spisek | CEO | Leadership |
Samone V. | Associate Director, Accounting | Leadership |
Daniela Červená | Chief Accountant | Leadership |
Pavel Solský | Chief Financial & Commercial Officer | Leadership |
Jiří Lísal | COO | Leadership |
Geoffrey Hodge | CEO, Sotio US | Leadership |
Radek Špíšek | CEO | Leadership |
Norbert Prenzel | Head Of Business Development And Licensing | Leadership |
Martin Steegmaier | Chief Scientific Officer | Leadership |
Lenka Palova Jelinkova | Director Translational Science | Leadership |
Gaëtan Decherf | CFO At Sotio Biotech AG | Leadership |
Michal Janek | Director Of Finance | Leadership |
Robyn Hunter | Chief Financial Officer | Leadership |
Dana Tomaszewski | Vice President Information Technology | Leadership |
Ann Ranger | VP Translational Medicine And Biomarkers | Leadership |
Kati Räsänen | Director ADC Discovery | Leadership |
Alise Reicin | Strategic Advisor | Board & advisors |
Josep Tabernero | Strategic Advisor | Board & advisors |
Anthony W. Tolcher | Strategic Advisor | Board & advisors |
Kapil Dhingra | Strategic Advisor | Board & advisors |
5 more people are available in the full profile.
Complete people profiles for SOTIO
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by SOTIO
SOTIO has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include CytunePharma.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Immunostimulatory agents and conjugated monoclonal antibodies for cancer are developed. | cytunepharma.com | Nantes, France | 2007 | Aug 2018 | •••• |
Complete acquisition details for SOTIO
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of SOTIO
3 dated milestones of SOTIO across 8 years, from founding to its latest funding, stage changes and deals.
- Founded SOTIO is founded.
- Exit Acquired by PPF Group.
- Acquisition Acquires CytunePharma.
Web traffic of SOTIO
The website of SOTIO (sotio.com) receives about 4.1K visits a month and ranks #4,207,043 among all websites worldwide, #5,196 in Biotechnology and Pharmaceuticals.
- Monthly visits4.1K
▼ 5.7% vs previous month
- Unique visitors1.9K
per month
- Global rank#4,207,043
among all websites
- Category rank#5,196
Health · Biotechnology and Pharmaceuticals
- Bounce rate43%
- Pages per visit1.6
- Average visit7 sec
- DevicesDesktop 49% · Mobile 51%
Websites whose visitors overlap most with SOTIO. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| biopharmguy.com | 100% | #377,294 | View details |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Sotio
Complete news archive for SOTIO
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about SOTIO
SOTIO was founded in 2010.
SOTIO is headquartered in Prague, Czechia.
Radek Spisek is the CEO of SOTIO, as recorded in our data.
Annual revenue of SOTIO is $8.12K as on Dec 31, 2021.
SOTIO Biotech is engaged in the development of next-generation immunotherapies for cancer treatment. The companys pipeline includes internally developed and in-licensed candidates targeting various solid tumor types. Solutions such as antibody-drug conjugates and immunocytokines are being advanced through clinical development to provide safer and more effective treatments. The focus is placed on translating scientific innovation into patient benefits within the oncology sector.
SOTIO offers SOT106, SOT109, and Nanrilkefusp alfa.
SOTIO has made 1 acquisition, including CytunePharma.
SOTIO has 1 investor. Key investors include PPF Group.
SOTIO operates through Sotio Biotech A.S..
Yes. SOTIO was acquired by PPF Group in June 2012.